Anaerobic Biotechnology

What Anaerobic Biotechnology does

Anaerobic Biotechnology (四川厌氧生物科技有限责任公司) is a Chengdu-based clinical-stage live biotherapeutic company founded in 2019 as a technology spin-off from the Ministry of Agriculture Biogas Research Institute. The company operates a proprietary bacterial strain resource library of 30,000+ preserved strains spanning 2,600+ species and 400+ genera, including approximately 76% of globally reported human gut-isolated species. Its core technology platform, branded 'from strain to drug,' integrates high-throughput aerobic and ppm-level anaerobic screening (60,000+ strains/day culture throughput), functional strain discovery via bioinformatics prediction and animal model validation, high-density fermentation and freeze-drying (achieving 10^11 CFU/g with 2-year shelf-life stability), and a GMP-compliant CMC platform. The clinical pipeline comprises KAL-001, a vaginal quadruple Lactobacillus live bacterial capsule now in Phase III for bacterial vaginosis; KAL-002, an intestinal formula bacterial drug now in Phase II for radiation enteritis and chemotherapy-induced diarrhea; and KAL-005, an early-stage recombinant program for recurrent C. difficile infection. The company is the first in China to have both a multi-strain vaginal and intestinal live bacterial drug in clinical development, and holds 60+ core invention patents.

The company operates multiple revenue streams: out-licensing of innovative live bacterial drugs (exemplified by the February 2025 Greater China exclusive licensing agreement with Shenzhen-listed Wanzei Shares / 万泽股份, stock code 000534.SZ), CRO/CDMO service contracts covering strain isolation, functional mining, one-stop CMC development, and high-throughput platform setup for pharmaceutical and academic customers, and consumer health products (益生菌固体饮料 probiotic solid beverages, female intimate care gels/powders, and pet gut microbiome products under the Fuchong Technology / 复宠科技 subsidiary including FMTiPet capsules and metagenomic sequencing services) commercialized through brand partnerships and a direct commercial channel. The GMP manufacturing facility under construction at Tianfu International Bio-town (~9,100 sqm, ~1 billion RMB planned investment) is intended to support both internal pipeline supply and external CDMO customers. Key partners include Wanzei Pharmaceutical for drug development and commercialization, Huangshi Dairy for probiotic ingredient co-development, Mege Genetics for microbiology research services, and Sichuan Agricultural University for pet FMT clinical infrastructure.

Go-to-market is hybrid: clinical-stage pharmaceutical revenue flows through enterprise licensing and co-development agreements with established pharma players (transactional licensing fees and prospective royalties post-approval), while CRO/CDMO services are sold via a direct B2B sales team targeting pharmaceutical companies, universities, and research institutions, and consumer products reach end-users through brand partnerships with consumer health and pet product companies. The company has raised over 100 million RMB cumulatively across angel (2020), Pre-A (2021, tens of millions), Series A (August 2022, 100M+ RMB co-led by Daotong Investment and Chengdu Science & Technology Innovation Investment), and a strategic round from Wanzei Shares (September 2023). Headcount exceeds 100 with 70%+ graduate-degree personnel, including a 50+ scientist microbial medicine research team led by founder/Chief Scientist Dr. Cheng Lei, whose team published a discovery on a fourth bacteria-archaea methanogenesis pattern in Nature in January 2025.

Name

Anaerobic Biotechnology

Legal name

四川厌氧生物科技有限责任公司

Website

https://scyysw.cn

Company type

Private

Founded year

2019

Operating status

Operating

Headcount range

11–50 employees

Short description

Anaerobic Biotechnology is a Chengdu-based clinical-stage live biotherapeutic company that develops Class I multi-strain live bacterial drugs (KAL-001 vaginal, KAL-002 intestinal) and consumer microbiome products from a proprietary library of 30,000+ bacterial strains, serving pharmaceutical partners and consumer health markets.

Ownership category

akta.pro rank

Product category

Microbiome Therapeutics

NAICS

Biological Product (except Diagnostic) Manufacturing (325414), Pharmaceutical Preparation Manufacturing (325412), Research and Development in Biotechnology (except Nanobiotechnology) (541714)

SIC

Biological Products, (No Disgnostic Substances) (2836), Pharmaceutical Preparations (2834), Medicinal Chemicals & Botanical Products (2833)

akta.pro primary industry

Engineered Microbial Therapeutics (synthetic biology, gene circuits) (HLAAAFAD)

akta.pro secondary industries

Microbiome Manufacturing, Formulation & Delivery Technologies (encapsulation, spores, oral delivery) (HLAAAFAJ), Microbiome Analytics, Sequencing & Bioinformatics Platforms (HLAAAFAI), Raw Materials & Critical Reagents Supply Services (media, resins, single-use) (HLAAAKAI), Probiotics & Digestive Health Supplements (CRADAGAF)

Keywords

• Live bacterial drugs
• Microbiome therapeutics
• Probiotic manufacturing
• Anaerobic strain library
• Microecological CRO

Headquarters

HQ city

Chengdu

HQ country

China

HQ region

Asia

Offices3 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Technology or R&D, Operations, Infrastructure, Supply Chain

Revenue model

1. Live Bacterial Innovative Drug Development & Licensing: Revenue from R&D and development of Class I biological live bacterial drugs, with commercial outcomes through out-licensing agreements (e.g., Greater China exclusive licensing agreement with Wanzei Pharma). Pipeline includes KAL-001 (vaginal), KAL-002 (intestinal), and KAL-005.
2. Consumer Health & Wellness Products: Revenue from commercialized microecological health products including probiotics solid beverages, feminine antibacterial care gels, female lactic acid bacteria live antibacterial powder, and pet microecological products. Sold through brand partnerships and direct commercial channels.
3. CRO/CDMO Services: Contract research and manufacturing services including strain resource development, functional strain mining, one-stop CMC development, and high-throughput strain screening platform setup services. Targets pharmaceutical companies, universities, research institutes, hospitals, and enterprises.

Go-to-market motion2 records

Distribution channels4 records

Marketing channels5 records

Core offering

Anaerobic Biotechnology develops Class I biological live bacterial innovative drugs (LBTs) and provides full-chain 'from strain to drug' microecological development services built on a proprietary strain library of 30,000+ bacterial strains. Its core drug pipeline includes KAL-001 (vaginal multi-strain Lactobacillus drug, Phase III), KAL-002 (intestinal formula bacterial drug, Phase II), and KAL-005 (for recurrent C. difficile infection). The company also offers CRO/CDMO services spanning strain isolation, functional strain mining, CMC development, and high-throughput platform construction, and operates a parallel consumer health portfolio (probiotic beverages, feminine care, and pet microbiome products via subsidiary 复宠科技).

Product overview

Anaerobic Biotechnology is a microecological pharmaceutical and consumer health company offering a comprehensive platform of technology services and products. The core offerings include: (1) Drug products - KAL-001 (vaginal quadruple Lactobacillus capsule, Phase III), KAL-002 (intestinal formula bacterial drug, Phase II), and KAL-005 (for r-CDI); (2) Consumer health products - probiotic beverages, feminine care gels and powders, pet health products including FMTiPet capsules and metagenomic testing services; (3) Technology platforms - high-throughput strain screening, functional strain discovery, process formulation, and production platforms; (4) Services - strain isolation, culture, mining, CMC development, and high-throughput platform construction services. The company operates a strain resource library with 30,000+ bacterial strains as the foundation for all products and services.

Differentiator

Problem solved

Functional benefit

Brands

• 复宠科技 (Pet-day by day / 复宠DBD): Subsidiary brand focused on pet gut microbiota health, offering pet FMT products, probiotic formulas, DNA testing services, and related pet health solutions. Launched in July 2024.

Products and services

• KAL-001 (Vaginal Quadruple Lactobacillus Live Bacteria Capsule, 阴道用四联乳杆菌活菌胶囊) Class I innovative biological product — vaginal quadruple Lactobacillus live bacterial capsule for treating female vaginal inflammation including recurrent bacterial vaginosis. China's first multi-strain live bacterial drug to enter clinical research, currently in Phase III clinical trials. Subject to exclusive Greater China licensing to Wanzei Shares (000534.SZ).
• KAL-002 (Intestinal Formula Bacterial Drug, 肠道配方菌药) Class I innovative biological intestinal formula bacterial drug for treating gastrointestinal diseases including radiation enteritis and chemotherapy-induced diarrhea. China's first intestinal formula bacterial drug to receive clinical approval, currently in Phase II clinical trials.
• KAL-005 (Recombinant Bacterial Drug for r-CDI) Recombinant bacterial drug for Clostridioides difficile infection (r-CDI) treatment, currently in early development stage.
• FMTiPet Gut Microecology Capsule (FMTiPet肠道微生态胶囊) Pet gut microecology capsule for intestinal microbiome transplantation (FMT) in pets, containing comprehensively screened and processed gut microbiota, distributed through subsidiary 复宠科技.
• Pet Gut Microbiome Metagenomic Sequencing Service (宠物肠道微生物宏基因组检测) Pet gut microbiome metagenomic sequencing service for analyzing pet gut microbiota composition and changes, offered as a companion diagnostic to FMT and probiotic products.
• Probiotic Solid Beverage (益生菌固体饮料) Multi-strain probiotic solid beverage with advanced encapsulation technology for natural gut flora regulation, improving constipation, diarrhea, and enhancing intestinal immunity.
• Female Intimate Care Antibacterial Gel (女性私护抑菌凝胶) Female intimate care antibacterial gel with prebiotics and glycogen to promote beneficial bacteria growth and regulate vaginal micro-environment.
• Female Lactic Acid Bacteria Live Antibacterial Powder (女性乳酸菌活菌抑菌粉) Female lactic acid bacteria live antibacterial powder with clinically validated strains to replenish beneficial vaginal bacteria and inhibit harmful bacteria growth.
• High-Throughput Bacterial Separation Service (高通量细菌分离服务) Contract research service offering non-targeted and targeted bacterial separation from various sources including human feces, animal feces, fermented food, soil, water samples, and plants, using the company's high-throughput aerobic/anaerobic dual platform.
• Strain Culture Service (菌株代培养服务) Contract strain culture service for customer-provided strains using the company's aerobic/anaerobic platforms, delivering customized forms including glycerol tubes and fresh bacterial solution.
• Functional Strain Mining Service (功效菌株挖掘服务) Full-chain functional strain mining service from bioinformatics prediction to in vitro and in vivo evaluation, covering bioinformatics, microbiology, cell function, and animal model assessment modules.
• One-Stop CMC Development Service (一站式CMC开发服务) Complete Chemistry, Manufacturing, and Controls (CMC) development service including process development, scale-up, lyophilization, formulation, and quality control, with 20+ project experience and access to 100+ assay methods.
• High-Throughput Strain Screening Platform Setup Service (高通量菌株筛选平台搭建服务) One-stop high-throughput microbial separation, culture, and identification automation platform construction service for laboratories, including platform planning, equipment configuration, installation, and training.
• Microecological Product Cooperation Service (微生态产品合作) Microecological product cooperation service covering probiotic supplements, feminine care, pet health, and other consumer health product co-development with brand partners.
• Proprietary Strain Co-Development Service (自有菌株联合开发) Co-development service using the company's proprietary strain library of 30,000+ bacterial strains spanning 2,600+ species, enabling joint strain resource development with external partners.

Quantifiable outcome

• KAL-001 is China's first multi-strain live bacterial drug to enter clinical research
• +3 more outcomes

Named customers3 records

Segments5 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature9 records

Partnerships

Five partnerships are on record, tiered core and important.

• 万泽医药 (Wanzei Pharmaceutical)coreStrategic or Co-development Partner · 30 April 2026Expanded strategic cooperation agreement with Wanzei Pharmaceutical following initial licensing deal. Deepens collaboration in clinical development, regulatory affairs, and commercial strategy for microecological live bacterial drugs in the Chinese market.
• 皇氏乳业 (Huangshi Dairy Co., Ltd.)coreStrategic or Co-development Partner · 21 April 2025Strategic cooperation focused on probiotic strain library development and product co-creation. Announced 'Bama probiotic strain library' achievement and launched cooperation to develop functional probiotic ingredients and health products for the dairy and health food market.
• 广东美格基因科技有限公司 (Guangdong Mege Genetics Technology Co., Ltd.)importantStrategic or Co-development Partner · 13 November 2024Strategic cooperation for high-throughput bacterial separation and culture research services. Combines Anaerobic Biotechnology's proprietary strain isolation platform with Mege Genetics' microbiome omics service capabilities to create a leading microbiology research service ecosystem.
• 四川农业大学 (Sichuan Agricultural University)coreStrategic or Co-development Partner · 14 May 2024Established China's first 'Pet Intestinal Flora Transplantation Specialty' and 'China Pet Flora Transplantation Specialty Alliance' with Sichuan Agricultural University Teaching Animal Hospital. Jointly developing pet-specific microbiome-based health solutions including pet FMT products and services.
• 农业农村部沼气科学研究所 (Ministry of Agriculture Biogas Research Institute)coreStrategic or Co-development Partner · 1 January 2019The company's founding shareholder and technology origin. Anaerobic Biotechnology was spin-off from China's earliest anaerobic microbiology key laboratory under the Ministry of Agriculture, leveraging over 20 years of anaerobic microbiology research expertise. The institute's Director Wang Dengshan served as founding shareholder representative.

Scale indicators8 records

Recent moves7 records

Expansion highlights7 records

Direct peers

• Seres Therapeutics: Pioneering US-based microbiome therapeutics company developing live biotherapeutic products (LBPs) for serious diseases including SER-109 (VOWST) for recurrent C. difficile infection. Most directly comparable global peer given the focus on live bacterial drugs and clinical-stage pipeline; both companies target similar indications including CDI and inflammatory conditions.
• Vedanta Biosciences: Clinical-stage US microbiome company developing defined bacterial consortia as therapeutics. Directly comparable to Anaerobic Biotechnology's multi-strain formulation approach (KAL-001 is a 4-strain product, similar to Vedanta's VE303). Both companies have built proprietary strain libraries and pursue CMC-heavy pharmaceutical development pathways.
• MaaT Pharma: France-based late-stage microbiome therapeutics company developing standardized full-ecosystem microbiome therapies (MaaT013, MaaT033) for acute graft-versus-host disease and oncology-supportive care. Comparable to Anaerobic Biotechnology's KAL-002 targeting radiation enteritis and chemotherapy-induced diarrhea in cancer patients.
• Finch Therapeutics: US-based microbiome therapeutics company developing FIN-211 for recurrent C. difficile infection and inflammatory bowel disease using full-consortium microbial therapy. Comparable to Anaerobic Biotechnology's multi-strain approach; both companies compete in the CDI space (overlapping with KAL-005).
• 4D pharma: UK-based clinical-stage microbiome therapeutics company (now merged with Siolta Therapeutics) developing live biotherapeutics across multiple indications including oncology, respiratory, and CNS diseases. Comparable platform approach of single-strain and multi-strain LBPs from proprietary libraries.

Emerging players

• Novome Biotechnologies: US-based clinical-stage company pioneering engineered microbial therapeutics, with lead program NOV-001 in Phase 1/2 clinical development. Comparable to KAL-005 (recombinant bacterial drug for r-CDI) and represents the engineered microbiome therapeutic subcategory.
• Assembly Biosciences: US-based clinical-stage biotech with a microbiome program developing rationally-designed Live Biotherapeutic Products for inflammatory diseases. Comparable to Anaerobic Biotechnology's pipeline in addressing inflammatory conditions through microbiome-based approaches.

Broad incumbents

• BioGaia: Sweden-based established probiotic company developing clinically validated Lactobacillus reuteri strains for consumer health and prescription products. Comparable to Anaerobic Biotechnology's consumer health products and probiotic solid beverage business, though BioGaia has global commercial scale while Anaerobic is China-focused.
• Chr. Hansen: Global bioscience company with a major probiotics and cultures business (now merged with Novozymes as Novonesis). Comparable broad incumbent in the strain library, probiotic manufacturing, and consumer health categories where Anaerobic Biotechnology also operates.

Regional players

• Zai Lab: Shanghai-based clinical-stage biopharmaceutical company developing and commercializing innovative therapeutics for China and global markets, with multiple Phase III assets. Comparable Chinese clinical-stage biotech profile and a potential future partner/acquirer for Anaerobic Biotechnology's ex-China rights.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat5 records

Key risks6 records

Key highlights6 records

Customer concentration

Compliance6 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles4 records

Subsidiaries1 record

Funding overview

Funding rounds2 records

Investors2 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Anaerobic Biotechnology